Avacta Therapeutics (AIM: AVCT) has appointed experienced biotechnology finance executive Mats Blom to its Board of Directors, where he will also serve as Chair of the Audit Committee.

Avacta Therapeutics (AIM: AVCT) has settled an accelerated deferred convertible bond repayment of £2.613 million in cash, reducing the remaining principal under the facility to £12 million.

Avacta (AIM: AVCT) has granted a substantial package of share options to its management team, including 13.4 million options to chief executive Christina Coughlin, as part of an incentive and

Accelerated Amortized Payment of Convertible Bond Installment

Avacta Therapeutics (AIM: AVCT) has appointed healthcare executive Dr Patrick Vink to its board as non-executive deputy chairman and senior independent director.

Avacta Therapeutics (AIM: AVCT) has secured a significant regulatory milestone after reaching an agreement with the US Food and Drug Administration on the pivotal trial design for its lead cancer

Avacta Group PLC announced that all resolutions were passed at its Annual General Meeting, with overwhelming shareholder support for each proposal.

Avacta Therapeutics (AIM: AVCT) has reported strong progress across its oncology pipeline in the first half of 2026, highlighting advances in both its clinical programmes and balance sheet ahead of

Avacta Therapeutics plc (AIM: AVCT) has strengthened its balance sheet after completing an oversubscribed £9 million equity fundraising, with proceeds earmarked primarily for reducing outstanding convertible bond debt and supporting

Avacta Group PLC (AIM: AVCT) unveiled encouraging new clinical data for its lead oncology candidate AVA6000 (faridoxorubicin) at the ASCO 2026 annual meeting, highlighting both promising efficacy and a potentially

Avacta Therapeutics (AIM: AVCT) has announced a boardroom transition, with Richard Hughes to be appointed non-executive chairman following the company’s Annual General Meeting on 22 June 2026.